Search results: (10000)
News Efficacy and Safety of Dupilumab in the Treatment of Severe Asthma Insufficiently Controlled by Standard Therapy – Current Clinical Practice Data
If severe bronchial asthma with type 2 inflammation is insufficiently controlled by combined maintenance therapy, dupilumab – a recombinant monoclonal antibody inhibiting the signaling pathway of interleukins 4 and 13 – can be added. What is its efficacy in clinical practice? We summarize findings from 3 recent retrospective studies.
News Neuraxpharm Introduces a New Form of Medical Cannabis
Since November 2022, a new medication containing an active full-spectrum cannabis extract – Naxiva Panaxol from Neuraxpharm – has been available in the Czech Republic. The cannabis extract is offered in collaboration with Panaxia Labs Israel. Both companies are key players in the European medical cannabis market. Their agreement ensures the distribution of these products not only in the Czech Republic but also in Switzerland and Germany.
News Impact of Comorbidities on the Efficacy of Ceftaroline Fosamil in Complicated Skin and Soft Tissue Infections − Pooled Analysis of 3 Studies
In 3 randomized Phase III studies, ceftaroline fosamil demonstrated non-inferiority in treating complicated skin and soft tissue infections (cSSTI) compared to vancomycin + aztreonam. A recent pooled analysis of these 3 studies evaluated the impact of age and comorbidities on clinical outcomes.
News Extract of Medical Cannabis Now Available for Czech Patients. What Benefits Does It Bring?
At the end of 2022, a new drug based on cannabis extract Naxiva Panaxol by Neuraxpharm was approved in the Czech Republic. It can be prescribed by specialists treating patients with chronic intractable pain. The treatment is covered by public health insurance.
News Dressing Solutions for Better Wound Care
Although wounds at different stages of healing require different types of treatment, the essential part of any dressing change is cleaning the wound and its surroundings from tissue debris and microorganisms and protecting it from reinfection. Modern dressing solutions facilitate easy cleaning and moisturizing of wounds. Effective treatment also brings clinical and economic benefits.
News Patient with a History of DOAC Usage in Neurological ICU with Stroke – Case Study
How should we approach patients with a stroke who are taking direct oral anticoagulants (DOACs) and correctly assess the situation? When should we administer the available antidote according to guidelines? The following case study from the Regional Hospital Liberec illustrates this increasingly common situation.
News Colours of Sepsis 2023: Antimicrobial Stewardship is a Necessity. The Spectrum of Effective Antimicrobial Modalities has Expanded to Include Another Combination
Inappropriate antibiotic (ATB) treatment is associated with high mortality, while unrestricted use of broad-spectrum antibiotics drives resistance development. Thus, the decision to deploy antibiotics becomes a choice between the current and future patient. Antimicrobial stewardship (AMS) is an essential strategy in daily operations. Extending the spectrum of antimicrobial agents is equally crucial in combatting resistant bacterial strains. A symposium on this theme was part of the expert program at this year's 'festival of intensive medicine' Colours of Sepsis, held in late January in Ostrava.
News INFOGRAPHIC: Diagnostic Algorithm for Cardiac Amyloidosis
What examinations are needed when cardiac amyloidosis is suspected? Which tests can distinguish transthyretin amyloidosis from systemic disease caused by immunoglobulin light chains? We bring you a clear diagnostic scheme according to the recommendations of the European Society of Cardiology (ESC).
.
News Current Position of Venetoclax in the Treatment of AML − Hope for a Better Prognosis?
The treatment of acute myeloid leukemia (AML) remained stagnant for a long time, with many new drugs emerging only in the past few years. One of the newest and most important is the Bcl-2 anti-apoptotic protein inhibitor venetoclax.
News Venetostart – The First Comprehensive Mobile Application with Practical Information for Venetoclax Treatment
Abbvie has developed the comprehensive mobile application Venetostart with practical information needed in clinical practice for administering venetoclax (Venclyxto), which is indicated for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML).
News Immunomodulation and Romiplostim − What Does the Recently Published iROM Study Say?
Primary immune thrombocytopenia (ITP) is caused by an immunity disorder, involving not only the production of antibodies but also changes in cytokine levels, predominance of Th1 lymphocytes over Th2, increase in Th17 cells, and conversely a decrease in T-regulatory lymphocytes (Tregs). One treatment option is the use of thrombopoietin receptor agonists (TPO-RA), which primarily increase platelet production. Recently, attention has also been focused on their potential immunomodulatory effects and protolerogenic effect associated with Tregs activation, which was the subject of the Swiss iROM study.
News ICIS Report: Potential of TPO-RA as Early Immunomodulatory Treatment of Immune Thrombocytopenia
The report from the meeting of the Intercontinental Cooperative ITP Study Group (ICIS) in 2022 in Lenzerheide, Switzerland, published late last year in the British Journal of Haematology, discusses the potential of early treatment of immune thrombocytopenia with thrombopoietin receptor agonists (TPO-RA) in achieving a disease remission sustainable without further therapy.
News Impact of Azacitidine Maintenance Therapy on Survival of Patients with AML in Remission Depending on Initial Chemotherapy
The QUAZAR AML-001 study showed that oral azacitidine maintenance therapy significantly prolongs relapse-free survival (RFS) and overall survival (OS) in patients with acute myeloid leukemia (AML) in first remission after intensive chemotherapy (including induction ± consolidation therapy), who are not candidates for hematopoietic stem cell transplantation (HSCT), compared to placebo. In October 2023, results of a subgroup analysis of patients stratified according to the use/non-use of consolidation chemotherapy and the number of consolidation chemotherapy cycles administered before entering the study were published.
News Brief from ASH 2021: News and Advances in CLL Treatment
The summary from the first day of the 63rd American Society of Hematology (ASH) Congress in Atlanta in December 2021 brought several new advancements in the treatment of chronic lymphocytic leukemia (CLL). Dr. Brian Koffman from the CLL Society provided commentary on these developments.
News Bimekizumab – Higher Chance of Complete Skin Healing in Moderate to Severe Psoriasis?
In August 2021, the European Medicines Agency (EMA) approved bimekizumab (Bimzelx LP) as the first psoriasis treatment that selectively and directly inhibits interleukins IL-17A and IL-17F. It is intended for the treatment of moderate to severe plaque psoriasis in adults for whom systemic treatment is appropriate. The approval is based on three Phase III clinical studies in which bimekizumab demonstrated a very high rate of skin healing compared to placebo and active treatments like ustekinumab and adalimumab, as well as good tolerability.